Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Total Non-Current Liabilities (2020 - 2025)

Bioventus (BVS) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $439.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 15.31% year-over-year to $439.8 million, compared with a TTM value of $439.8 million through Dec 2025, down 15.31%, and an annual FY2025 reading of $439.8 million, down 15.31% over the prior year.
  • Total Non-Current Liabilities was $439.8 million for Q4 2025 at Bioventus, down from $515.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $937.6 million in Q4 2022 and bottomed at -$257.4 million in Q3 2023.
  • Average Total Non-Current Liabilities over 5 years is $496.8 million, with a median of $548.5 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities plummeted 137.73% in 2023, then skyrocketed 326.39% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $601.9 million in 2021, then soared by 55.78% to $937.6 million in 2022, then tumbled by 39.03% to $571.6 million in 2023, then dropped by 9.17% to $519.2 million in 2024, then fell by 15.31% to $439.8 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for BVS at $439.8 million in Q4 2025, $515.0 million in Q3 2025, and $484.2 million in Q2 2025.